Cite
MLA Citation
Lingfang Xia et al.. “Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study.” Journal for immunotherapy of cancer, vol. 10, no. 1, 2022, p. . http://access.bl.uk/ark:/81055/vdc_100148213479.0x000007